Evidence map›Paper›PMID 22393088›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2012

Assessing the impact of a cooperative group trial on breast cancer care in the medicare population.

Pamela R Soulos, James B Yu, Kenneth B Roberts, Ann C Raldow, Jeph Herrin, Jessica B Long, Cary P Gross

Abstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Long-term Impact of CALGB 9343 on Radiation Utilization.The Journal of surgical research · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Surgery in the Older Patient with Breast Cancer.Current oncology reports · 2019
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Pamela R SoulosYale School of Medicine, Primary Care Center, New Haven, CT 06520, USA.
James B Yu
Kenneth B Roberts
Ann C Raldow
Jeph Herrin
Jessica B Long
Cary P Gross
Health Research and Educational Trust · US

Funding

Use and Outcomes of Radiation Therapy for Medicare Patients with Common CancersR01CA149045 · NCI · YALE UNIVERSITY · PI GROSS, CARY P. · 2010 to 2012
$1.5M
NCI NIH HHS R01 CA149045PHS HHS 1R01C4149045-01
6 · The paper itself

Abstract

purposeThe Cancer and Leukemia Group B (CALGB) C9343 trial found that adjuvant radiation therapy (RT) provided minimal benefits for older women with breast cancer. Although treatment guidelines were changed to indicate that some women could forego RT, the impact of the C9343 results on clinical practice is unclear. PATIENTS AND

methodsWe used the Surveillance, Epidemiology, and End Results (SEER) -Medicare data set to assess the use of adjuvant RT in a sample of women ≥ 70 years old diagnosed with stage I breast cancer from 2001 to 2007 who fulfilled the C9343 inclusion criteria. We used log-binomial regression to estimate the relation between publication of C9343 and use of RT in the full sample and across strata of patient and health system characteristics.

resultsOf the 12,925 Medicare beneficiaries in our sample (mean age, 77.7 years), 76.5% received RT. Approximately 79% of women received RT before study publication compared with 75% after (adjusted relative risk of receiving RT postpublication v prepublication: 0.97; 95% CI, 0.95 to 0.98). Although use of RT was lower after the trial within all strata of age and life expectancy, the magnitude of this decrease did not differ significantly by strata. For instance, among patients with life expectancy less than 5 years, RT use decreased by 3.7%, from 44.4% prepublication to 40.7% postpublication. Among patients with life expectancy ≥ 10 years, RT use decreased by 3.0%, from 92.0% to 89.0%.

conclusionThe C9343 trial had minimal impact on the use of RT among older women in the Medicare population, even among the oldest women and those with shorter life expectancies.

Indexed as

Life ExpectancyMedicareAgedAged, 80 and overAge FactorsBreast NeoplasmsCombined Modality TherapyDisease-Free SurvivalFemaleHumansMastectomy, SegmentalNeoplasm InvasivenessNeoplasm StagingPrognosisRadiotherapy, AdjuvantRisk Assessment

Identifiers

PMID22393088
PMCPMC3383112
OpenAlexW2172164484

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.